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M A J O R A R T I C L E
Adjunctive Granulocyte Colony-Stimulating Factor
for Treatment of Septic Shock Due to Melioidosis
Allen C. Cheng,1,2 Dianne P. Stephens,3 Nicholas M. Anstey,1,2 and Bart J. Currie1,2
1Menzies School of Health Research and 2Division of Medicine and 3Intensive Care Unit, Royal Darwin Hospital, Northern Territory Clinical
School, Flinders University, Darwin, Australia
Melioidosis, caused by the intracellular pathogen Burkholderia pseudomallei, is endemic in northern Australia
and Southeast Asia. Risk factors for this infection have also been associated with functional neutrophil defects.
Because of this, granulocyte colony-stimulating factor (G-CSF) was adopted for use in patients with septic
shock due to melioidosis in December 1998. We compared the mortality rates from before and after the
introduction of G-CSF therapy at the Royal Darwin Hospital (Darwin, Australia) during the period of 1989–
2002. The mortality rate decreased from 95% to 10% after the introduction of G-CSF. Risk factors, the duration
of illness before presentation, and the severity of illness were similar in both groups. A smaller decrease in
mortality among patients in the intensive care unit who did not have melioidosis was observed, suggesting
that other changes in management did not account for the magnitude of the benefit seen. We conclude that
G-CSF may have contributed to the reduction in the mortality rate among patients with septic shock due to
melioidosis.
Melioidosis, the infection caused by the environmental
gram-negative bacillus Burkholderia pseudomallei, is en-
demic in Southeast Asia and northern Australia [1]. It
is the most common bacteremic pneumonia–associated
cause of death in the Top End of northern Australia
[2], and, at our institution, it is the most common cause
of septic shock [3].
Granulocyte colony-stimulating factor (G-CSF) is a
naturally occurring cytokine that primarily increases
neutrophil production. It has demonstrable effects on
neutrophil function, including chemotaxis, superoxide
production, and intracellular killing [4]. Other studies
have demonstrated its effects on anti-inflammatory
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cytokines [5] and intracellular concentrations of anti-
biotics [6]. Although subsequent study results were neg-
ative [7, 8], in 1998, a clinical trial was published that
suggested that a subgroup of patients with severe pneu-
monia may benefit from the administration of recom-
binant human G-CSF (filgrastim) [9]. The literature
about animal and human studies of the use of G-CSF
for treating sepsis was examined and discussed by the
intensivist and infectious diseases specialists at Royal
Darwin Hospital (Darwin, Australia), and it was de-
cided that G-CSF would be added to the means of
treating septic shock in a specific attempt to reduce the
almost universal mortality rate (95%) associated with
septic shock due to melioidosis.
We previously reported our general experience with
the use of G-CSF for treating septic shock. In that study,
6 patients in the G-CSF group and no patients in the
control group had melioidosis [3]. We were unable to
draw conclusions about the use of G-CSF for treating
melioidosis because of the small number of cases ac-
crued at that stage. Thus, with the benefit of further
experience, we wished to audit our use of G-CSF for
the treatment of melioidosis and to explore pos-
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sible confounders for the reduction in the mortality rate that
we observed.
The empirical management of community-acquired sepsis
in the Top End of the Northern Territory in Australia (where
melioidosis is endemic) includes the use of ceftriaxone (2 g iv
before transfer to the hospital) on the basis of its partial in
vitro activity against B. pseudomallei [10] and its long half-life
[11]. In the hospital, ceftriaxone is used for empirical ward
management for patients who are not suspected of having me-
lioidosis, and ceftazidime is used if melioidosis is suspected on
the basis of risk factors and exposure. In January 1998, mer-
openem was introduced for the empirical management of com-
munity-acquired sepsis in the wet season for patients admitted
to the intensive care unit (ICU). All patients admitted to the
ICU with sepsis during the wet season receive meropenem as
initial therapy until culture results exclude melioidosis.
METHODS
The Royal Darwin Hospital is the referral center for all patients
in the Top End of Australia, which extends to north Western
Australia, an area of 516,945 km2 with ∼150,000 inhabitants.
In this area, there are only 2 urban centers with populations
of 15000: Darwin (population, ∼90,000) and Katherine (pop-
ulation, ∼8000).
G-CSF therapy was adopted for use by a consensus decision
of the intensivist and infectious diseases specialists at Royal
Darwin Hospital in November 1998, in an attempt to reduce
the almost universal rate of mortality associated with septic
shock due to melioidosis seen before that time. Recombinant
human G-CSF (filgrastim; Neupogen [Amgen]) was adminis-
tered to all patients admitted to the ICU with septic shock,
including those with melioidosis, usually within 1 h after meet-
ing the criteria for septic shock [12]. There was no delay in
administration, because a microbiological diagnosis was not
required for a case to meet the criteria for treatment with G-
CSF. G-CSF was administered at a dosage of 300 mg per day,
given intravenously, and therapy was continued for 10 days (or
longer, if the patient’s condition continued to meet the defi-
nition of septic shock). The course was terminated earlier if
the patient was discharged from the ICU or if the total neu-
trophil count was 175,000 cells/mL. Standard treatment for
septic shock in the ICU at the Royal Darwin Hospital includes
aggressive fluid management, vasopressor support with nor-
epinephrine, early continuous venovenous hemofiltration for
acute renal failure or severe acidosis, and early intervention
with mechanical ventilation, as required.
An intensivist was first appointed in the Northern Territory
in March 1998. The ICU administration before that time con-
sisted of specialist anesthesiologists in conjunction with inter-
nists. The appointment of an intensivist resulted in many
changes to management protocols. Changes introduced in 1998
included the introduction of a closed ICU model, the use of
early and aggressive enteral feeding, the use of protective ven-
tilation strategies [13], and the more-aggressive use of hemo-
dynamic monitoring. Other protocols were introduced during
the period of 1998–2002, including a sedation protocol [14],
a protocol for the use of physiological steroids for septic shock
[15], and an infection-control protocol that has resulted in a
decrease in the rates of nosocomial infection.
A prospective database has stored clinical details for patients
with melioidosis since 1989. We included data for patients who
had been admitted to the ICU during the period of August
1989 through September 2002 and who had culture-confirmed
melioidosis that met the definition of septic shock. Clinical
details of each case were abstracted onto standardized data
forms. The use of G-CSF and possible confounding factors were
analyzed for 2 time periods: December 1998 through September
2002 (patients given G-CSF; the “G-CSF group”) and before
December 1998 (patients who were not given G-CSF; the “his-
torical control group”). We defined mortality as a death that
occurred during hospitalization. WBC counts were assessed on
the day of ICU admission, and the highest WBC count during
the subsequent 14 days was also noted.
To estimate the cumulative effect of the appointment of an
intensivist and the subsequent change in ICU patient manage-
ment, we examined mortality in the ICU before and after March
1998, excluding patients with culture-confirmed melioidosis.
For this analysis, we examined the records for all patients ad-
mitted to the ICU during the period of 1 March 1992 through
17 July 2001. Because G-CSF was used in the treatment of
patients with nonmelioidosis septic shock and has previously
been reviewed [3], we considered the mortality rate among
patients who did not receive a diagnosis of sepsis, pneumonia,
or melioidosis—the conditions most commonly associated with
septic shock.
Ethics approval for this review was obtained from the Human
Research Ethical Committee of the Department of Human Ser-
vices and the Menzies School of Health Research (Darwin).
Statistical analysis was conducted using Intercooled Stata for
Windows, version 7.0 (Stata), using Fisher’s exact test and the
Mann-Whitney U test for comparison of nonparametric data,
except where indicated in the text. Statistical significance was
defined as .P ! .05
RESULTS
During the period of August 1989 through September 2002,
341 patients were admitted to the hospital with culture-
confirmed melioidosis; of these patients, 42 had septic shock
requiring admission to the ICU. Greater numbers of patients
with septic shock were seen in 1998–1999 (9 patients) and
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Figure 1. Kaplan Meier curve for survival of melioidosis-associated
septic shock, starting from the day of hospital admission, for recipients
of granulocyte colony-stimulating factor (line) and the historical control
group (dotted line).
2000–2001 (13 patients), mostly as a result of heavy monsoonal
rainfall.
During the period of December 1998 through September
2002, 21 patients were administered G-CSF for septic shock
due to B. pseudomallei (G-CSF group), with 2 deaths (mortality
rate, 9.5%). In contrast, 21 patients were admitted to the ICU
during the period of August 1989 through November 1998 with
septic shock due to B. pseudomallei (historical control group),
with a single survivor (mortality rate, 95.2%; , byP ! .001
Fisher’s exact test). The timing of deaths is illustrated in figure
1 (hazard ratio, 18.3; , by log-rank test). A summaryP ! .001
of results is provided in table 1.
Patients had a similar median age (G-CSF group, 49 years;
historical control group, 50 years; significant [NS]),Pp not
with lower proportions of female patients (24% vs. 43%) and
patients of Aboriginal ethnicity (62% vs. 81%; ) in thePpNS
G-CSF group, although 2 patients in the G-CSF group were
indigenous New Zealanders. There were no significant differ-
ences in the median durations of illness before presentation
(G-CSF group, 3 days; historical control group, 4 days; Pp
). Similar proportions of patients were from the urban cen-NS
ters of Darwin or Katherine, compared with remote commu-
nities (G-CSF group, 42%; historical control group, 38%;
).PpNS
Site and severity of illness. Pneumonia was the most com-
mon type of infection and was present in all but 2 patients in
the G-CSF group. Ten patients (48%) in the G-CSF group and
6 patients (29%) in the historical control group had different
types of infection ( ). Risk factors were similar in bothPpNS
groups, with 12 patients (57%) in the historical control group
and 13 (62%) in the G-CSF group having diabetes ( ).PpNS
The mean APACHE II scores were 24.8 in the G-CSF group
and 25.6 in the historical control group ( ).PpNS
Management. Use of carbapenems (imipenem or mero-
penem) was more common in the G-CSF group than in the
historical control group (90% vs. 29%; ). A higher pro-P ! .001
portion of patients in the historical control group received
ceftriaxone as initial therapy (86% vs. 38%; ). ThreeP ! .01
patients in the historical control group did not receive either
ceftazidime or a carbapenem, because they died !48 h after
admission and before receiving a diagnosis of melioidosis; all
3 patients received ceftriaxone. All patients in the G-CSF group
and 15 patients in the historical control group received cefta-
zidime or a carbapenem before or !24 h after septic shock was
diagnosed.
Safety. Of the 21 patients in the G-CSF group, 3 (14%)
had WBC counts of 175,000 cells/mL. Three patients in the G-
CSF group had electrocardiographic and/or biochemical evi-
dence of myocardial damage; their WBC counts at this time
were 10,400, 18,000, and 58,000 cells/mL. None of these cardiac
events were fatal, and 1 patient had evidence of myocardial
damage at presentation to the hospital. One patient in the
historical control group had a myocardial infarction.
WBC counts at hospital admission were similar in both
groups (median WBC count for G-CSF group, 12,400 cells/mL
[range, 4900–40,200 cells/mL]; median WBC count for histor-
ical control group, 9100 cells/mL [range, 2000–36,900 cells/
mL]; ) It was not possible to determine peak WBCPpNS
counts in the historical control group because of the short
duration of survival; patients in the G-CSF group had a varying
increase in the WBC count (median peak WBC count, 38,500
cells/mL; range, 16,300–90,900 cells/mL) after a median of 6
days (range, 1–11 days).
Analysis of all ICU admissions and mortality. During the
period of 1 March 1992 through 14 August 2001, data were
available for 3147 patients admitted to the ICU, 2647 of whom
did not have melioidosis, sepsis, or pneumonia. Significant di-
agnoses (i.e., those that occurred in 12% of patients), apart
from sepsis, melioidosis, and pneumonia, were multiple trauma
(9.3%) and head trauma (6.8%), chronic obstructive airway
disease and asthma (5.5%), intracranial hemorrhage (5.4%),
cardiac failure and cardiogenic shock (5.2%), neurological dis-
ease (4.6%), cardiac arrest (4.2%), gastrointestinal perforation
and obstruction (3.1%), drug overdose (2.7%), and seizures
(2.3%).
In the period before 1 March 1998, the mean APACHE II
score for 1669 patients was 16.6, and the observed mortality
rate was 23.7%. In the period starting on 1 March 1998, the
mean APACHE II score for 978 patients was 17.8, and the
observed mortality rate was 21.3%. In a Poisson regression
comparison of the period starting on 1 March 1998 with the
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Table 1. Summary of results of a study of adjunctive granulocyte colony-stimulating factor (G-CSF)







(n p 21) P
Mortality 2 (9.5) 20 (95.2) !.001
Australian Aboriginal race 13 (62) 17 (81) NS
Age, median years (range) 49 (28–64) 50 (11–74) NS
Male sex 16 (76) 12 (57) NS
Duration of illness before presentation,
median days (range) 3 (1–8) 4 (1–90) NS
Patient from urban setting 9 (42) 8 (38) NS
Pneumonia present 19 (90) 21 (100) NS
Other type of infection present 10 (48) 6 (28) NS
Diabetes 13 (57) 12 (62) NS
Mean APACHE II score (range) 24.8 (13–33) 25.6 (13–44) NS
Receipt of carbapenem 19 (90) 6 (28) !.001
Time to receipt of ceftazidime or carbapenem,
median days (range)a 0 (15 to 0) 0 (2 to 5) .007
Use of ceftriaxone as initial therapy 8 (38) 18 (86) .004
Time to receipt of ceftriaxone, ceftazidime,
or carbapenem, median days (range)a 0 (15 to 0) 0 (5 to 2) NS
WBC count, median cells/mL (range)
At admission to the ICU 12,400 (4900–40,200) 9100 (2000–36,900) NS
Peak 38,500 (16,300–90,900) Not analyzed …
NOTE. Data are no. (%) of patients, unless otherwise indicated. ICU, intensive care unit; NS, not significant.
a Time was relative to day of diagnosis of septic shock (negative values indicate that the antibiotic was received before
the diagnosis of septic shock). Four patients in the historical control group did not receive ceftazidime or carbapenem.
period before that date, the APACHE II–adjusted mortality
ratio was 0.77 ( ).P ! .002
DISCUSSION
The rationale for introducing G-CSF for the treatment of septic
shock due to melioidosis was based on the following data avail-
able at the time: B. pseudomallei has been shown to survive
and multiply within cells, including neutrophils [16]; comorbid
conditions associated with mortality due to and development
of melioidosis [2], including diabetes, chronic renal failure, and
hazardous alcohol use, are also associated with functional neu-
trophil defects [17–19]; G-CSF has been shown to improve the
outcomes of sepsis in animal models and to improve neutrophil
function in vitro [19, 20]; evidence available at that time sug-
gested that G-CSF therapy may benefit patients with multilobar
pneumonia—although no benefit was seen overall [9]—and
patients also had improvements in diabetic foot ulcers asso-
ciated with increased neutrophil function [21]; and G-CSF is
generally well tolerated, with an extensive history of use for the
treatment of neutropenia [4].
Our subsequent experience, with an associated reduction in
the mortality rate for this condition from 95% to 10%, has
been in sharp contrast to the findings of large, published studies
of G-CSF for treatment of nonneutropenic infection. In recent
studies, no benefit was attributed to the use of G-CSF in patients
with community-acquired multilobar pneumonia [7] or severe
pneumonia and severe sepsis [8, 22]. In the study by Root et
al. [8], investigators suggested that delays in administering G-
CSF might have contributed to the negative results. We have
always administered G-CSF very shortly after admission to the
ICU and after the diagnosis of septic shock.
In performing this retrospective review of our experience
with G-CSF, we considered several potential confounders, but
we believe that each of them would be unlikely to result in
such a large reduction in the mortality rate. Could the ap-
pointment of an intensivist have reduced mortality to this ex-
tent? Clearly, the appointment of an intensivist has been as-
sociated with a modest improvement in the mortality rate at
our institution, with a decrease in the rate of mortality due to
septic shock (for which mortality is confounded by routine G-
CSF use) [3] and in critically ill patients with other diagnoses.
Although other studies examining the effect of intensivists on
mortality are likely to suffer from a significant publication bias,
the magnitude of the effect at Royal Darwin Hospital (a 36%
reduction in the mortality rate, with adjustment for severity of
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illness) is in line with the findings of published studies [23–
26]. Thus, it is unlikely that this factor is entirely responsible
for the 90% reduction in mortality among patients with me-
lioidosis-associated septic shock.
Could an earlier diagnosis and earlier administration of an-
tibiotics have resulted in this effect? Ceftriaxone was used more
often as initial therapy in the historical control group, and the
G-CSF group received ceftazidime or a carbapenem antibiotic
earlier. A retrospective review from Thailand suggested that
there were poorer outcomes in patients treated initially with
ceftriaxone or cefotaxime than in those treated with ceftazidime
or carbapenems [27]. However, that study did not control for
time to receipt of antibiotics or severity of illness, and patients
treated with a third-generation cephalosporin were more likely
to be bacteremic (78% vs. 62%). Patients treated empirically
with ceftazidime or a carbapenem had a lower mortality rate
than did those who were treated with a third-generation ceph-
alosporin and whose therapy was changed to ceftazidime or a
carbapenem (42% vs. 61%). This difference, a relative rate re-
duction of 31%, is unlikely to fully account for the difference
in mortality seen in our series, although we acknowledge that
it potentially represents a significant confounding factor. In the
absence of data from clinical trials, we continue to advocate
the use of ceftriaxone (2 g iv, which is greater than the con-
ventional dose used in Thailand, 20 mg/kg iv) for the empirical
management of adult community-acquired sepsis in our region.
Ceftriaxone has in vitro activity against B. pseudomallei and
other common bacteria that cause community-acquired sepsis,
it is available in remote settings, and it has a long half-life,
which is important when considering delays in medical evac-
uation from remote settings [10, 11].
Delays in treatment due to transport may have impacted on
the course of the illness, but we did not find any differences
in the geographical locations of patients in the 2 groups. Such
delays before admission would be expected to result in more
severely unwell patients, and we did not find any significant
differences between groups in the severity of illness at admission
to the ICU.
Could other changes in management have accounted for this
effect? Although meropenem has yet to be tested in a clinical
trial, another carbapenem antibiotic, imipenem, was tested in
Thailand [28]. Although that trial was underpowered as a result
of withdrawal of funding, no difference in mortality was seen
between groups after enrolment of 214 patients with culture-
confirmed melioidosis (the overall mortality rate was 36.9%).
This suggests that, if such a difference exists, it would likely be
small. With regard to the other changes made to management
protocols around this time, only protective ventilation strategies
[13] and the use of aggressive monitoring with early goal–
directed resuscitation [29] have been demonstrated to have an
impact on mortality.
Could changes in admission criteria for the ICU have selected
for patients who were more likely to survive? There have not
been any changes to ICU admission policies with respect to
patient selection during this time. We found that the G-CSF
and historical control groups had similar severities of illness,
as measured by APACHE II scores. Every patient in this study
with melioidosis had the presence of comorbidities recognized
as a risk factor for melioidosis.
Are other clinical features and in vivo models consistent with
a beneficial effect? Such features may have included a quicker
resolution of fever and shorter duration of blood culture pos-
itivity; however, such comparisons would not be meaningful
as a result of the short duration of survival of patients before
G-CSF began to be used. A research group recently studied G-
CSF as an adjunct to ceftazidime in a Balb/c mouse model of
acute melioidosis [30]. In these studies, there was no benefit
associated with the use of G-CSF with ceftazidime. However,
given that findings from previous animal studies using other
pathogens have failed to translate to humans in clinical trials,
such animal models may not be indicative of benefits of this
therapy for humans.
A previous concern has been that G-CSF use may increase
the incidence and severity of sepsis-induced acute respiratory
distress syndrome (ARDS) [31]. We found that we could not
readily retrospectively identify ARDS in patients with pneu-
monia, but in all 4 clinical trials of G-CSF for pneumonia [7–
9, 22], there was not a significant increase in the incidence of
ARDS, organ dysfunction, or serious adverse events.
Within the limitations of the study design, we observed a
decrease in the mortality rate from 95% to 10%, which was
associated with the use of G-CSF. Although we cannot exclude
the possibility that this may have resulted from a convergence
of confounding factors, including the presence of an intensivist
and the earlier use of effective antibiotics, the decrease in mor-
tality is in excess of that which might be ascribed to these
factors. It is hypothesized that the prompt use of G-CSF in our
patients with comorbid conditions associated with neutrophil
dysfunction may have contributed, at least in part, to the re-
duction in mortality associated with the intracellular pathogen
B. pseudomallei. These results deserve further scrutiny; in con-
junction with colleagues in Thailand, we are planning a pla-
cebo-controlled, randomized, controlled trial.
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